Curative effects of repaglinide and repaglinide combining insulin glargine on newly diagnosed type 2 diabetes
YAO Lu
SUN Jian-min
LV Xiao-feng
Abstract：Objective To compare the difference in blood glucose level in the patients with newly diagnosed type 2 diabetes treated with only repaglinide or repaglinide combining insulin glargine for 12 weeks. Methods The patients (n=48) were chosen from the General Hospital of PLA Beijing Military Area Command from Jan. 2012 to Jan. 2013, and randomly divided into repaglinide group and combining group (each n=24). The repaglinide group was orally given repaglinide (0.5 mg initially) before meals and combining group was given oral repaglinide and hypodermic injection of insulin glargine (6 u initially) at every 8 pm. The dosages of the drugs were adjusted according to patients’ blood glucose level. The levels of fasting blood glucose (FBG), 2-hour postprandial blood glucose (2-h PBG) and HbA1C, and control time of blood glucose were observed in two groups after treatment for 12 weeks. Results Compared with repaglinide group, the levels of FBG [(5.9±1.6) mmol/L vs. (6.8±1.5) mmol/L], 2-h PBG [(8.8±0.9) mmol/L vs. (9.2±0.8) mmol/L] and HBA1C [(7.4±0.5)%vs. (7.8±1.3)%] were lower, and control time of blood glucose was shorter [(6.1±1.3) d vs. (8.9±2.5) d] in combining group. Conclusion Repaglinide combining insulin glargine has better curative effect on type 2 diabetes than only repaglinide, which can improve blood glucose reaching normal level.
Keywords：RepaglinideInsulin glargineType 2 diabetes
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 481-482 )